Skip to main content
Top
Published in: Journal of Neurology 3/2013

01-03-2013 | Review

Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system

Author: Dirk Dressler

Published in: Journal of Neurology | Issue 3/2013

Login to get access

Abstract

Botulinum toxin (BoNT) has gained widespread use for the treatment of overactive muscles, overactive exocrine glands and, most recently, non-muscular pain conditions. Autonomic conditions treated with BoNT include achalasia, gastroparesis, sphincter of Oddi spasms, and unspecific esophageal spasms in gastroenterology and prostate disorders in urology. BoNT’s use for autonomic conditions related to neurology includes various forms of bladder dysfunction (detrusor sphincter dyssynergia, idiopathic detrusor overactivity, neurogenic detrusor overactivity, urinary retention and bladder pain syndrome), pelvic floor disorders (pelvic floor spasms and anal fissures), hyperhidrosis (axillary, palmar, and plantar hyperhidrosis, diffuse sweating, Frey’s syndrome) and hypersalivation (hypersalivation in Parkinsonian syndromes, motor neuron disease, neuroleptic use, and cerebral palsy). Hyperhidrosis, hypersalivation, some forms of bladder dysfunction and pelvic floor disorders can easily be treated by neurologists. Most bladder dysfunctions require cooperation with urology departments.
Literature
1.
go back to reference Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, CambridgeCrossRef Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, CambridgeCrossRef
2.
go back to reference Qerama E, Fuglsang-Frederiksen A, Jensen TS (2010) The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 23:602–610PubMedCrossRef Qerama E, Fuglsang-Frederiksen A, Jensen TS (2010) The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 23:602–610PubMedCrossRef
3.
go back to reference Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922PubMed Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922PubMed
4.
go back to reference Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71:24–26PubMed Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71:24–26PubMed
5.
go back to reference Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029PubMedCrossRef Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029PubMedCrossRef
6.
go back to reference Beleggia F, Beccia E, Imbriani E, Basciani M, Intiso D, Cioffi R et al (1997) The use of type A botulin toxin in the treatment of detrusor-sphincter dyssynergia. Arch Ital Urol Androl 69(Suppl 1):61–63PubMed Beleggia F, Beccia E, Imbriani E, Basciani M, Intiso D, Cioffi R et al (1997) The use of type A botulin toxin in the treatment of detrusor-sphincter dyssynergia. Arch Ital Urol Androl 69(Suppl 1):61–63PubMed
7.
go back to reference Petit H, Wiart L, Gaujard E, Le Breton F, Ferrière JM, Lagueny A (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36:91–94PubMedCrossRef Petit H, Wiart L, Gaujard E, Le Breton F, Ferrière JM, Lagueny A (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36:91–94PubMedCrossRef
8.
go back to reference Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79:715–717PubMedCrossRef Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79:715–717PubMedCrossRef
9.
go back to reference de Sèze M, Petit H, Gallien P, de Sèze MP, Joseph PA, Mazaux JM et al (2002) Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62PubMedCrossRef de Sèze M, Petit H, Gallien P, de Sèze MP, Joseph PA, Mazaux JM et al (2002) Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62PubMedCrossRef
10.
go back to reference Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E (2005) Placebo-controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76:1670–1676PubMedCrossRef Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E (2005) Placebo-controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76:1670–1676PubMedCrossRef
11.
go back to reference Chen SL, Bih LI, Chen GD, Huang YH, You YH, Lew HL (2010) Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. Arch Phys Med Rehabil 91:340–344PubMedCrossRef Chen SL, Bih LI, Chen GD, Huang YH, You YH, Lew HL (2010) Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. Arch Phys Med Rehabil 91:340–344PubMedCrossRef
12.
go back to reference Schurch B, Hodler J, Rodic B (1997) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 63:474–476PubMedCrossRef Schurch B, Hodler J, Rodic B (1997) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 63:474–476PubMedCrossRef
13.
go back to reference Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL (2009) Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil 90:832–836PubMedCrossRef Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL (2009) Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil 90:832–836PubMedCrossRef
14.
go back to reference Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRef Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRef
15.
go back to reference Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96:848–852PubMedCrossRef Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96:848–852PubMedCrossRef
16.
go back to reference Sahai A (2006) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 97:413PubMedCrossRef Sahai A (2006) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 97:413PubMedCrossRef
17.
go back to reference Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo-controlled trial. J Urol 177:2231–2236PubMedCrossRef Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo-controlled trial. J Urol 177:2231–2236PubMedCrossRef
18.
go back to reference Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100:1302–1306PubMedCrossRef Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100:1302–1306PubMedCrossRef
19.
go back to reference Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B (2008) Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 19:905–909PubMedCrossRef Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B (2008) Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 19:905–909PubMedCrossRef
20.
go back to reference Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217–222PubMedCrossRef Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217–222PubMedCrossRef
21.
go back to reference Lie KY, Wong MY, Ng LG (2010) Botulinum toxin a for idiopathic detrusor overactivity. Ann Acad Med Singapore 39:714–715PubMed Lie KY, Wong MY, Ng LG (2010) Botulinum toxin a for idiopathic detrusor overactivity. Ann Acad Med Singapore 39:714–715PubMed
22.
go back to reference Gomez CS, Kanagarajah P, Gousse A (2010) The use of botulinum toxin a in idiopathic overactive bladder syndrome. Curr Urol Rep 11:353–359PubMedCrossRef Gomez CS, Kanagarajah P, Gousse A (2010) The use of botulinum toxin a in idiopathic overactive bladder syndrome. Curr Urol Rep 11:353–359PubMedCrossRef
23.
go back to reference Sahai A, Dowson C, Khan MS, GKT Botulinum Study Group (2010) Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75:552–558PubMedCrossRef Sahai A, Dowson C, Khan MS, GKT Botulinum Study Group (2010) Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75:552–558PubMedCrossRef
24.
go back to reference Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ et al (2005) Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo-controlled, crossover trial. Urol 174:1873–1877CrossRef Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ et al (2005) Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo-controlled, crossover trial. Urol 174:1873–1877CrossRef
25.
go back to reference Sahai A, Dowson C, Khan MS, Dasgupta P (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509–1515PubMedCrossRef Sahai A, Dowson C, Khan MS, Dasgupta P (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509–1515PubMedCrossRef
26.
go back to reference Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR et al (2007) Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 69:69–73PubMedCrossRef Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR et al (2007) Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 69:69–73PubMedCrossRef
27.
go back to reference Kuo HC, Liao CH, Chung SD (2010) Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 8:919–926CrossRef Kuo HC, Liao CH, Chung SD (2010) Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 8:919–926CrossRef
28.
go back to reference Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697CrossRef Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697CrossRef
29.
go back to reference Kenelly MJ, Kang J (2003) Botulinum-A toxin injections as a treatment fro refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 8:46–53CrossRef Kenelly MJ, Kang J (2003) Botulinum-A toxin injections as a treatment fro refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 8:46–53CrossRef
30.
go back to reference Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79–87PubMed Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79–87PubMed
31.
go back to reference Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRef Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRef
32.
go back to reference Bagi P, Biering-Sørensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:495–498PubMedCrossRef Bagi P, Biering-Sørensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:495–498PubMedCrossRef
33.
go back to reference Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 174:196–200PubMedCrossRef Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 174:196–200PubMedCrossRef
34.
go back to reference Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH (2005) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25:110–115CrossRef Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH (2005) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25:110–115CrossRef
35.
go back to reference Grosse J, Kramer G, Stöhrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRef Grosse J, Kramer G, Stöhrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRef
36.
go back to reference Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:37–41PubMedCrossRef Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:37–41PubMedCrossRef
37.
go back to reference Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J (2005) Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 12:2543–2546PubMed Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J (2005) Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 12:2543–2546PubMed
38.
go back to reference Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24:231–236PubMedCrossRef Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24:231–236PubMedCrossRef
39.
go back to reference Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989PubMedCrossRef Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989PubMedCrossRef
40.
go back to reference Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:232–236PubMedCrossRef Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:232–236PubMedCrossRef
41.
go back to reference Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030–1034PubMedCrossRef Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030–1034PubMedCrossRef
42.
go back to reference Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535PubMedCrossRef Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535PubMedCrossRef
43.
go back to reference Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193–1197PubMedCrossRef Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193–1197PubMedCrossRef
44.
go back to reference Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C et al (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41:335–340PubMedCrossRef Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C et al (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41:335–340PubMedCrossRef
45.
go back to reference Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH (2002) Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59:325–327PubMedCrossRef Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH (2002) Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59:325–327PubMedCrossRef
46.
go back to reference Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH (2003) Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139–143PubMedCrossRef Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH (2003) Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139–143PubMedCrossRef
47.
go back to reference Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848PubMedCrossRef Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848PubMedCrossRef
48.
go back to reference Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870PubMedCrossRef Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870PubMedCrossRef
49.
go back to reference Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH et al (2006) Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68:1091–1096PubMedCrossRef Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH et al (2006) Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68:1091–1096PubMedCrossRef
50.
go back to reference Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E (2006) The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176:328–330PubMedCrossRef Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E (2006) The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176:328–330PubMedCrossRef
51.
go back to reference Akbar M, Abel R, Seyler TM, Bedke J, Haferkamp A, Gerner HJ et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639–645PubMedCrossRef Akbar M, Abel R, Seyler TM, Bedke J, Haferkamp A, Gerner HJ et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639–645PubMedCrossRef
52.
go back to reference Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165:1107–1110PubMedCrossRef Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165:1107–1110PubMedCrossRef
53.
go back to reference Kuo HC (2003) Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61:550–554PubMedCrossRef Kuo HC (2003) Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61:550–554PubMedCrossRef
54.
go back to reference Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG (1992) Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70:387–389PubMedCrossRef Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG (1992) Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70:387–389PubMedCrossRef
55.
go back to reference Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871–875PubMedCrossRef Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871–875PubMedCrossRef
56.
go back to reference Kuo HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75:170–174PubMedCrossRef Kuo HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75:170–174PubMedCrossRef
57.
go back to reference Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704–709PubMedCrossRef Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704–709PubMedCrossRef
58.
go back to reference Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70:463–468PubMedCrossRef Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70:463–468PubMedCrossRef
59.
go back to reference Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 179:1031–1034PubMedCrossRef Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 179:1031–1034PubMedCrossRef
60.
go back to reference Brin MF, Vapnek JM (1997) Treatment of vaginismus with botulinum toxin injections. Lancet 349:252–253PubMedCrossRef Brin MF, Vapnek JM (1997) Treatment of vaginismus with botulinum toxin injections. Lancet 349:252–253PubMedCrossRef
61.
go back to reference Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G (2006) Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 51:635–641PubMed Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G (2006) Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 51:635–641PubMed
62.
go back to reference Gunter J, Brewer A, Tawfik O (2004) Botulinum toxin A for vulvodynia: a case report. J Pain 5:238–240PubMedCrossRef Gunter J, Brewer A, Tawfik O (2004) Botulinum toxin A for vulvodynia: a case report. J Pain 5:238–240PubMedCrossRef
63.
go back to reference Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG (2004) Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44:46–50PubMedCrossRef Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG (2004) Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44:46–50PubMedCrossRef
64.
go back to reference Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG (2005) The use of botulinum toxin type A (Botox) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 112:247–249PubMedCrossRef Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG (2005) The use of botulinum toxin type A (Botox) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 112:247–249PubMedCrossRef
65.
go back to reference Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108:915–923PubMedCrossRef Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108:915–923PubMedCrossRef
66.
go back to reference Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A (2000) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43:376–380PubMedCrossRef Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A (2000) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43:376–380PubMedCrossRef
67.
go back to reference Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 8613:714–717CrossRef Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 8613:714–717CrossRef
68.
go back to reference Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39:1107–1111PubMedCrossRef Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39:1107–1111PubMedCrossRef
69.
go back to reference Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S et al (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44:1821–1826PubMedCrossRef Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S et al (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44:1821–1826PubMedCrossRef
70.
go back to reference Jost WH, Schimrigk K (1994) Therapy of anal fissure using botulin toxin. Dis Colon Rectum 37:1321–1324PubMedCrossRef Jost WH, Schimrigk K (1994) Therapy of anal fissure using botulin toxin. Dis Colon Rectum 37:1321–1324PubMedCrossRef
71.
go back to reference Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A (1994) Botulinum toxin for chronic anal fissure. Lancet 344(8930):1127–1128PubMedCrossRef Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A (1994) Botulinum toxin for chronic anal fissure. Lancet 344(8930):1127–1128PubMedCrossRef
72.
go back to reference Tranqui P, Trottier DC, Victor C, Freeman JB (2006) Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin. Can J Surg 49:41–55PubMed Tranqui P, Trottier DC, Victor C, Freeman JB (2006) Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin. Can J Surg 49:41–55PubMed
73.
go back to reference Festen S, Gisbertz SS, van Schaagen F, Gerhards MF (2009) Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure. Br J Surg 96:1393–1399PubMedCrossRef Festen S, Gisbertz SS, van Schaagen F, Gerhards MF (2009) Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure. Br J Surg 96:1393–1399PubMedCrossRef
74.
go back to reference Wollina U (2008) Pharmacological sphincterotomy for chronic anal fissures by botulinum toxin A. J Cutan Aesthet Surg 1:58–63PubMedCrossRef Wollina U (2008) Pharmacological sphincterotomy for chronic anal fissures by botulinum toxin A. J Cutan Aesthet Surg 1:58–63PubMedCrossRef
75.
go back to reference Strutton DR, Kowalski JW, Glaser DA, Stang PE (2004) US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51:241–248PubMedCrossRef Strutton DR, Kowalski JW, Glaser DA, Stang PE (2004) US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51:241–248PubMedCrossRef
76.
go back to reference Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276–278PubMedCrossRef Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276–278PubMedCrossRef
77.
go back to reference Heckmann M, Ceballos-Baumann AO, Plewig G (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:48893CrossRef Heckmann M, Ceballos-Baumann AO, Plewig G (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:48893CrossRef
78.
go back to reference Naumann M, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo-controlled trial. BMJ 323:596–599CrossRef Naumann M, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo-controlled trial. BMJ 323:596–599CrossRef
79.
go back to reference Naumann M, Lowe NJ, Kumar CR, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139:731–736PubMedCrossRef Naumann M, Lowe NJ, Kumar CR, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139:731–736PubMedCrossRef
80.
go back to reference Lowe PL, Cerdan-Sanz S, Lowe NJ (2003) Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis; efficacy and duration with repeated treatments. Dermatol Surg 29:5458CrossRef Lowe PL, Cerdan-Sanz S, Lowe NJ (2003) Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis; efficacy and duration with repeated treatments. Dermatol Surg 29:5458CrossRef
81.
go back to reference Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY et al (2007) Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 56:604–611PubMedCrossRef Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY et al (2007) Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 56:604–611PubMedCrossRef
82.
go back to reference Dressler D (2010) Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm 117:317–319PubMedCrossRef Dressler D (2010) Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm 117:317–319PubMedCrossRef
83.
go back to reference Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K (1997) Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136:548–552PubMedCrossRef Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K (1997) Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136:548–552PubMedCrossRef
84.
go back to reference Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K et al (1999) A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 140:677–680PubMedCrossRef Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K et al (1999) A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 140:677–680PubMedCrossRef
85.
go back to reference Schnider P, Moraru E, Kittler H, Binder M, Kranz G, Voller B et al (2001) Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol 145:289–293PubMedCrossRef Schnider P, Moraru E, Kittler H, Binder M, Kranz G, Voller B et al (2001) Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol 145:289–293PubMedCrossRef
86.
go back to reference Salmanpoor R, Rahmanian MJ (2002) Treatment of axillary hyperhidrosis with botulinum-A toxin. Int J Dermatol 41:428–430PubMedCrossRef Salmanpoor R, Rahmanian MJ (2002) Treatment of axillary hyperhidrosis with botulinum-A toxin. Int J Dermatol 41:428–430PubMedCrossRef
87.
go back to reference Heckmann M, Hyperhidrosis Study Group (2005) Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141:1255–1259PubMedCrossRef Heckmann M, Hyperhidrosis Study Group (2005) Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141:1255–1259PubMedCrossRef
88.
go back to reference Moffat CE, Hayes WG, Nyamekye IK (2009) Durability of botulinum toxin treatment for axillary hyperhidrosis. Eur J Vasc Endovasc Surg 38:188–191PubMedCrossRef Moffat CE, Hayes WG, Nyamekye IK (2009) Durability of botulinum toxin treatment for axillary hyperhidrosis. Eur J Vasc Endovasc Surg 38:188–191PubMedCrossRef
89.
go back to reference Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732PubMedCrossRef Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732PubMedCrossRef
90.
go back to reference Nelson L, Bachoo P, Holmes J (2005) Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plast Surg 58:228–232PubMedCrossRef Nelson L, Bachoo P, Holmes J (2005) Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plast Surg 58:228–232PubMedCrossRef
91.
go back to reference Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38PubMedCrossRef Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38PubMedCrossRef
92.
go back to reference Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS et al (2008) Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1707–1714PubMedCrossRef Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS et al (2008) Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1707–1714PubMedCrossRef
93.
go back to reference Naumann M, Flachenecker P, Bröcker EB, Toyka KV, Reiners K (1997) Botulinum toxin for palmar hyperhidrosis. Lancet 349:252PubMedCrossRef Naumann M, Flachenecker P, Bröcker EB, Toyka KV, Reiners K (1997) Botulinum toxin for palmar hyperhidrosis. Lancet 349:252PubMedCrossRef
94.
go back to reference Shelley WB, Talanin NY, Shelley ED (1998) Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38:227–229PubMedCrossRef Shelley WB, Talanin NY, Shelley ED (1998) Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38:227–229PubMedCrossRef
95.
go back to reference Naver H, Swartling C, Aquilonius SM (2000) Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 7:55–62PubMedCrossRef Naver H, Swartling C, Aquilonius SM (2000) Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 7:55–62PubMedCrossRef
96.
go back to reference Solomon BA, Hayman R (2000) Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42:1026–1029PubMedCrossRef Solomon BA, Hayman R (2000) Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42:1026–1029PubMedCrossRef
97.
go back to reference Vadoud-Seyedi J, Heenen M, Simonart T (2001) Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature. Dermatology 203:318–321PubMedCrossRef Vadoud-Seyedi J, Heenen M, Simonart T (2001) Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature. Dermatology 203:318–321PubMedCrossRef
98.
go back to reference Saadia D, Voustianiouk A, Wang AK, Kaufmann H (2001) Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57:2095–2099PubMedCrossRef Saadia D, Voustianiouk A, Wang AK, Kaufmann H (2001) Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57:2095–2099PubMedCrossRef
99.
go back to reference Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S (2002) Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28:822–827PubMedCrossRef Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S (2002) Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28:822–827PubMedCrossRef
100.
go back to reference Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM (2003) A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 149:1041–1045PubMedCrossRef Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM (2003) A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 149:1041–1045PubMedCrossRef
101.
go back to reference Pérez-Bernal AM, Avalos-Peralta P, Moreno-Ramírez D, Camacho F (2005) Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience. J Cosmet Dermatol 4:163–166PubMedCrossRef Pérez-Bernal AM, Avalos-Peralta P, Moreno-Ramírez D, Camacho F (2005) Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience. J Cosmet Dermatol 4:163–166PubMedCrossRef
102.
go back to reference Yamashita N, Shimizu H, Kawada M, Yanagishita T, Watanabe D, Tamada Y (2008) Local injection of botulinum toxin A for palmar hyperhidrosis: usefulness and efficacy in relation to severity. J Dermatol 35:325–329PubMedCrossRef Yamashita N, Shimizu H, Kawada M, Yanagishita T, Watanabe D, Tamada Y (2008) Local injection of botulinum toxin A for palmar hyperhidrosis: usefulness and efficacy in relation to severity. J Dermatol 35:325–329PubMedCrossRef
103.
go back to reference Dressler D (2010) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2–5 Dressler D (2010) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2–5
104.
go back to reference Baumann LS, Halem ML (2003) Systemic adverse effects after botulinum toxin type B (MYOBLOC) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139:226–227PubMed Baumann LS, Halem ML (2003) Systemic adverse effects after botulinum toxin type B (MYOBLOC) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139:226–227PubMed
105.
go back to reference Baumann L, Slezinger A, Halem M, Vujevich J, Mallin K, Charles C et al (2005) Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of MYOBLOC (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 31:263–270PubMedCrossRef Baumann L, Slezinger A, Halem M, Vujevich J, Mallin K, Charles C et al (2005) Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of MYOBLOC (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 31:263–270PubMedCrossRef
106.
go back to reference Baumann L, Frankel S, Welsh E, Halem M (2003) Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. Dermatol Surg 29:1057–1059PubMedCrossRef Baumann L, Frankel S, Welsh E, Halem M (2003) Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. Dermatol Surg 29:1057–1059PubMedCrossRef
107.
go back to reference Smith KC, Comite SL, Storwick GS (2007) Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 33:S88–S91PubMedCrossRef Smith KC, Comite SL, Storwick GS (2007) Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 33:S88–S91PubMedCrossRef
108.
go back to reference Lim EC, Seet RC (2007) Another injection-free method to effect analgesia when injecting botulinum toxin for palmar hyperhidrosis: cryoanalgesia. Dermatol Online J 13:25PubMed Lim EC, Seet RC (2007) Another injection-free method to effect analgesia when injecting botulinum toxin for palmar hyperhidrosis: cryoanalgesia. Dermatol Online J 13:25PubMed
109.
go back to reference Richards RN (2009) Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 13:253–256PubMed Richards RN (2009) Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 13:253–256PubMed
110.
go back to reference Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A (2004) Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 51:345–348PubMedCrossRef Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A (2004) Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 51:345–348PubMedCrossRef
111.
go back to reference Blaheta HJ, Vollert B, Zuder D, Rassner G (2004) Intravenous regional anesthesia (Bier’s block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol Surg 28:666–671CrossRef Blaheta HJ, Vollert B, Zuder D, Rassner G (2004) Intravenous regional anesthesia (Bier’s block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol Surg 28:666–671CrossRef
112.
go back to reference Patel R, Halem M, Zaiac M (2009) The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhidrosis with botulinum toxin injections. J Drugs Dermatol 8:948–951PubMed Patel R, Halem M, Zaiac M (2009) The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhidrosis with botulinum toxin injections. J Drugs Dermatol 8:948–951PubMed
113.
go back to reference Bosdotter Enroth S, Rystedt A, Covaciu L, Hymnelius K, Rystedt E, Nyberg R et al (2010) Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis. J Am Acad Dermatol 63:466–474PubMedCrossRef Bosdotter Enroth S, Rystedt A, Covaciu L, Hymnelius K, Rystedt E, Nyberg R et al (2010) Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis. J Am Acad Dermatol 63:466–474PubMedCrossRef
114.
go back to reference Davarian S, Kalantari KK, Rezasoltani A, Rahimi A (2008) Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol 49:75–79PubMedCrossRef Davarian S, Kalantari KK, Rezasoltani A, Rahimi A (2008) Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol 49:75–79PubMedCrossRef
115.
go back to reference Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301–304PubMedCrossRef Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301–304PubMedCrossRef
116.
go back to reference Sevim S, Dogu O, Kaleagasi H (2002) Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg 102:167–170PubMed Sevim S, Dogu O, Kaleagasi H (2002) Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg 102:167–170PubMed
117.
go back to reference Vadoud-Seyedi J (2004) Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 43:969–971PubMedCrossRef Vadoud-Seyedi J (2004) Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 43:969–971PubMedCrossRef
118.
go back to reference Campanati A, Bernardini ML, Gesuita R, Offidani A (2007) Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 17:52–54PubMed Campanati A, Bernardini ML, Gesuita R, Offidani A (2007) Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 17:52–54PubMed
119.
go back to reference Kinkelin I, Hund M, Naumann M, Hamm H (2000) Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 143:824–827PubMedCrossRef Kinkelin I, Hund M, Naumann M, Hamm H (2000) Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 143:824–827PubMedCrossRef
120.
go back to reference Santana-Rodríguez N, Clavo-Varas B, Ponce-González MA, Jarabo-Sarceda JR, Pérez-Alonso D, Ruiz-Caballero JA et al (2010) Primary frontal hyperhidrosis successfully treated with low doses of botulinum toxin A as a useful alternative to surgical treatment. J Dermatolog Treat [Epub ahead of print] Santana-Rodríguez N, Clavo-Varas B, Ponce-González MA, Jarabo-Sarceda JR, Pérez-Alonso D, Ruiz-Caballero JA et al (2010) Primary frontal hyperhidrosis successfully treated with low doses of botulinum toxin A as a useful alternative to surgical treatment. J Dermatolog Treat [Epub ahead of print]
121.
go back to reference Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K (2007) Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33:924–927PubMedCrossRef Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K (2007) Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33:924–927PubMedCrossRef
122.
go back to reference Schulze-Bonhage A, Schroder M, Ferbert A (1996) Botulinum toxin in the therapy of gustatory sweating. J Neurol 243:143–146PubMedCrossRef Schulze-Bonhage A, Schroder M, Ferbert A (1996) Botulinum toxin in the therapy of gustatory sweating. J Neurol 243:143–146PubMedCrossRef
123.
go back to reference Bjerkhoel A, Trobbe O (1997) Frey’s syndrome: treatment with botulinum toxin. J Laryngol Otol 111:839–844PubMedCrossRef Bjerkhoel A, Trobbe O (1997) Frey’s syndrome: treatment with botulinum toxin. J Laryngol Otol 111:839–844PubMedCrossRef
124.
go back to reference Laskawi R, Drobik C, Schönebeck C (1998) Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 108:381–384PubMedCrossRef Laskawi R, Drobik C, Schönebeck C (1998) Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 108:381–384PubMedCrossRef
125.
go back to reference von Lindern JJ, Niederhagen B, Bergé S, Hägler G, Reich RH (2000) Frey syndrome: treatment with type A botulinum toxin. Cancer 89:1659–1663CrossRef von Lindern JJ, Niederhagen B, Bergé S, Hägler G, Reich RH (2000) Frey syndrome: treatment with type A botulinum toxin. Cancer 89:1659–1663CrossRef
126.
go back to reference Dulguerov P, Quinodoz D, Cosendal G, Piletta P, Lehmann W (2000) Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg 122:821–827PubMedCrossRef Dulguerov P, Quinodoz D, Cosendal G, Piletta P, Lehmann W (2000) Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg 122:821–827PubMedCrossRef
127.
go back to reference Beerens AJ, Snow GB (2002) Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg 89:116–119PubMedCrossRef Beerens AJ, Snow GB (2002) Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg 89:116–119PubMedCrossRef
128.
go back to reference Kyrmizakis DE, Pangalos A, Papadakis CE, Logothetis J, Maroudias NJ, Helidonis ES (2004) The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg 62:840–844PubMedCrossRef Kyrmizakis DE, Pangalos A, Papadakis CE, Logothetis J, Maroudias NJ, Helidonis ES (2004) The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg 62:840–844PubMedCrossRef
129.
go back to reference de Bree R, Duyndam JE, Kuik DJ, Leemans CR (2009) Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:287–290PubMedCrossRef de Bree R, Duyndam JE, Kuik DJ, Leemans CR (2009) Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:287–290PubMedCrossRef
130.
go back to reference Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S (2010) Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 143:214–218PubMedCrossRef Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S (2010) Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 143:214–218PubMedCrossRef
131.
go back to reference Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, Rotteveel JJ (2003) The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 113:107–111PubMedCrossRef Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, Rotteveel JJ (2003) The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 113:107–111PubMedCrossRef
132.
go back to reference Jongerius PH, Rotteveel JJ, van den Hoogen F, Joosten F, van Hulst K, Gabreëls FJ (2001) Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 160:509–512PubMedCrossRef Jongerius PH, Rotteveel JJ, van den Hoogen F, Joosten F, van Hulst K, Gabreëls FJ (2001) Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 160:509–512PubMedCrossRef
133.
go back to reference Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112:82–86PubMedCrossRef Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112:82–86PubMedCrossRef
134.
go back to reference Suskind DL, Tilton A, Suskind DL, Tilton A (2002) Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112:73–81PubMedCrossRef Suskind DL, Tilton A, Suskind DL, Tilton A (2002) Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112:73–81PubMedCrossRef
135.
go back to reference Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreëls FJ, van Hulst K, van den Hoogen FJ (2004) Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 63:1371–1375PubMedCrossRef Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreëls FJ, van Hulst K, van den Hoogen FJ (2004) Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 63:1371–1375PubMedCrossRef
136.
go back to reference Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreëls FJ, van Hulst K, Rotteveel JJ (2004) Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114:620–627PubMedCrossRef Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreëls FJ, van Hulst K, Rotteveel JJ (2004) Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114:620–627PubMedCrossRef
137.
go back to reference Savarese R, Diamond M, Elovic E, Millis SR (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83:304–311PubMedCrossRef Savarese R, Diamond M, Elovic E, Millis SR (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83:304–311PubMedCrossRef
138.
go back to reference Banerjee KJ, Glasson C, O’Flaherty SJ (2006) Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol 48:883–887PubMedCrossRef Banerjee KJ, Glasson C, O’Flaherty SJ (2006) Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol 48:883–887PubMedCrossRef
139.
go back to reference Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough D (2008) Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol 50:123–128PubMed Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough D (2008) Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol 50:123–128PubMed
140.
go back to reference Wilken B, Aslami B, Backes H (2008) Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 39:200–204PubMedCrossRef Wilken B, Aslami B, Backes H (2008) Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 39:200–204PubMedCrossRef
141.
go back to reference Alrefai AH, Aburahma SK, Khader YS (2009) Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo-controlled trial. Clin Neurol Neurosurg 111:79–82PubMedCrossRef Alrefai AH, Aburahma SK, Khader YS (2009) Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo-controlled trial. Clin Neurol Neurosurg 111:79–82PubMedCrossRef
142.
go back to reference Ong LC, Wong SW, Hamid HA (2009) Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A. J Pediatr Neurol 7:141–145 Ong LC, Wong SW, Hamid HA (2009) Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A. J Pediatr Neurol 7:141–145
143.
go back to reference Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ (2010) Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 136:873–877PubMedCrossRef Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ (2010) Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 136:873–877PubMedCrossRef
144.
go back to reference Sriskandan N, Moody A, Howlett DC (2010) Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. Br J Oral Maxillofac Surg 48:58–60PubMedCrossRef Sriskandan N, Moody A, Howlett DC (2010) Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. Br J Oral Maxillofac Surg 48:58–60PubMedCrossRef
145.
go back to reference Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC (2011) Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol [Epub ahead of print] Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC (2011) Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol [Epub ahead of print]
146.
go back to reference Reddihough D, Graham HK (2011) Botulinum toxin type B for sialorrhea in children with cerebral palsy. Dev Med Child Neurol 53:488–489PubMedCrossRef Reddihough D, Graham HK (2011) Botulinum toxin type B for sialorrhea in children with cerebral palsy. Dev Med Child Neurol 53:488–489PubMedCrossRef
147.
go back to reference Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D (2011) Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 53:559–564PubMedCrossRef Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D (2011) Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 53:559–564PubMedCrossRef
148.
go back to reference Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH (2010) Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol 17(Suppl 2):109–121PubMedCrossRef Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH (2010) Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol 17(Suppl 2):109–121PubMedCrossRef
149.
go back to reference Bothwell JE, Clarke K, Dooley JM, Gordon KE, Anderson R, Wood EP et al (2002) Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 27:18–22PubMedCrossRef Bothwell JE, Clarke K, Dooley JM, Gordon KE, Anderson R, Wood EP et al (2002) Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 27:18–22PubMedCrossRef
150.
go back to reference Hassin-Baer S, Scheuer E, Buchman AS, Jacobson I, Ben-Zeev B (2005) Botulinum toxin injections for children with excessive drooling. J Child Neurol 20:120–123PubMedCrossRef Hassin-Baer S, Scheuer E, Buchman AS, Jacobson I, Ben-Zeev B (2005) Botulinum toxin injections for children with excessive drooling. J Child Neurol 20:120–123PubMedCrossRef
151.
go back to reference Pal PK, Calne DB, Calne S, Tsui JK (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54:244–247PubMedCrossRef Pal PK, Calne DB, Calne S, Tsui JK (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54:244–247PubMedCrossRef
152.
go back to reference Friedman A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35(Suppl 3):23–27PubMed Friedman A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35(Suppl 3):23–27PubMed
153.
go back to reference Carod Artal FJ (2003) Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands. Neurologia 18:280–284PubMed Carod Artal FJ (2003) Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands. Neurologia 18:280–284PubMed
154.
go back to reference Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106:93–96PubMedCrossRef Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106:93–96PubMedCrossRef
155.
go back to reference Porta M, Gamba M, Bertacchi G, Vaj P (2001) Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70:538–540PubMedCrossRef Porta M, Gamba M, Bertacchi G, Vaj P (2001) Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70:538–540PubMedCrossRef
156.
go back to reference Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454–457PubMedCrossRef Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454–457PubMedCrossRef
157.
go back to reference Bhatia KP, Münchau A, Brown P (1999) Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 67:697PubMedCrossRef Bhatia KP, Münchau A, Brown P (1999) Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 67:697PubMedCrossRef
158.
go back to reference Glickman S, Deaney CN (2001) Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 8:567–571PubMedCrossRef Glickman S, Deaney CN (2001) Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 8:567–571PubMedCrossRef
159.
go back to reference Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61:1279–1281PubMedCrossRef Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61:1279–1281PubMedCrossRef
160.
go back to reference Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688PubMedCrossRef Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688PubMedCrossRef
161.
go back to reference Tan EK, Lo YL, Seah A, Auchus AP (2001) Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 190:95–97PubMedCrossRef Tan EK, Lo YL, Seah A, Auchus AP (2001) Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 190:95–97PubMedCrossRef
162.
go back to reference Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I et al (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69:121–123PubMedCrossRef Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I et al (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69:121–123PubMedCrossRef
163.
go back to reference Manrique D (2005) Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Rev Bras Otorrinolaringol 71:556–559CrossRef Manrique D (2005) Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Rev Bras Otorrinolaringol 71:556–559CrossRef
164.
go back to reference Verma A, Steele J (2006) Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 34:235–237PubMedCrossRef Verma A, Steele J (2006) Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 34:235–237PubMedCrossRef
165.
go back to reference Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A et al (2007) Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson’s disease. Parkinsonism Relat Disord 13:299–303PubMedCrossRef Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A et al (2007) Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson’s disease. Parkinsonism Relat Disord 13:299–303PubMedCrossRef
166.
go back to reference Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M (2008) Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 255:545–550PubMedCrossRef Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M (2008) Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 255:545–550PubMedCrossRef
167.
go back to reference Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB et al (2009) Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 39:137–143PubMedCrossRef Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB et al (2009) Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 39:137–143PubMedCrossRef
168.
go back to reference Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J (2010) Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 207:593–597CrossRef Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J (2010) Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 207:593–597CrossRef
169.
go back to reference Ellies M, Laskawi R, Rohrbach-Volland S, Rödel R, Beuche W (2001) Blocking secretion of exocrine glands in the head-neck area by administration of botulinum toxin A. Therapy of a rare disease picture. HNO 49:807–813PubMedCrossRef Ellies M, Laskawi R, Rohrbach-Volland S, Rödel R, Beuche W (2001) Blocking secretion of exocrine glands in the head-neck area by administration of botulinum toxin A. Therapy of a rare disease picture. HNO 49:807–813PubMedCrossRef
170.
go back to reference Guntinas-Lichius O, Eckel HE (2002) Temporary reduction of salivation in laryngectomy patients with pharyngocutaneous fistulas by botulinum toxin A injection. Laryngoscope 112:187–189PubMedCrossRef Guntinas-Lichius O, Eckel HE (2002) Temporary reduction of salivation in laryngectomy patients with pharyngocutaneous fistulas by botulinum toxin A injection. Laryngoscope 112:187–189PubMedCrossRef
171.
go back to reference Ellies M, Rohrbach-Volland S, Arglebe C, Wilken B, Laskawi R, Hanefeld F (2002) Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatrics 33:327–330PubMedCrossRef Ellies M, Rohrbach-Volland S, Arglebe C, Wilken B, Laskawi R, Hanefeld F (2002) Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatrics 33:327–330PubMedCrossRef
172.
go back to reference Saberi FA, Schade H, Dressler D (2008) Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon’s duct occlusion. Toxicon 51(Suppl 1):44 Saberi FA, Schade H, Dressler D (2008) Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon’s duct occlusion. Toxicon 51(Suppl 1):44
173.
go back to reference Wabbels B, Förl M (2007) Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction. Ophthalmologe 104:771–776PubMedCrossRef Wabbels B, Förl M (2007) Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction. Ophthalmologe 104:771–776PubMedCrossRef
174.
go back to reference Hofmann RJ (2000) Treatment of Frey’s syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg 16:289–291PubMedCrossRef Hofmann RJ (2000) Treatment of Frey’s syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg 16:289–291PubMedCrossRef
175.
go back to reference Barañano DE, Miller NR (2004) Long-term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol 88:588–589PubMedCrossRef Barañano DE, Miller NR (2004) Long-term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol 88:588–589PubMedCrossRef
176.
go back to reference Kizkin S, Doganay S, Ozisik HI, Ozcan C (2005) Crocodile tears syndrome: botulinum toxin treatment under EMG guidance. Funct Neurol 20:35–37PubMed Kizkin S, Doganay S, Ozisik HI, Ozcan C (2005) Crocodile tears syndrome: botulinum toxin treatment under EMG guidance. Funct Neurol 20:35–37PubMed
177.
go back to reference Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J (1998) Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 65:111–114PubMedCrossRef Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J (1998) Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 65:111–114PubMedCrossRef
178.
go back to reference Keegan DJ, Geerling G, Lee JP, Blake G, Collin JR, Plant GT (2002) Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 86:43–46PubMedCrossRef Keegan DJ, Geerling G, Lee JP, Blake G, Collin JR, Plant GT (2002) Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 86:43–46PubMedCrossRef
179.
go back to reference Montoya FJ, Riddell CE, Caesar R, Hague S (2002) Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 16:705–709CrossRef Montoya FJ, Riddell CE, Caesar R, Hague S (2002) Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 16:705–709CrossRef
180.
go back to reference Kahle W, Leonhardt H, Platzer W (1979) Taschenatlas der Anatomie für Studium und Praxis. Band 3: Nervensystem und Sinnesorgane. 3., überarbeitete Auflage. Thieme-Verlag, Stuttgart Kahle W, Leonhardt H, Platzer W (1979) Taschenatlas der Anatomie für Studium und Praxis. Band 3: Nervensystem und Sinnesorgane. 3., überarbeitete Auflage. Thieme-Verlag, Stuttgart
Metadata
Title
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system
Author
Dirk Dressler
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 3/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6615-2

Other articles of this Issue 3/2013

Journal of Neurology 3/2013 Go to the issue